RT Journal Article
T1 Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment
A1 Sarabia De Ardanaz, Luis
A1 Andreu-Ubero, Jose M.
A1 Navidad-Fuentes, Miriam
A1 Ferrer-González, Miguel Ángel
A1 Ruíz Del Valle, Victor
A1 Salcedo-Bellido, Inmaculada
A1 Barrios-Rodríguez, Rocío
A1 Cáliz-Cáliz, Rafael
A1 Requena, Pilar
K1 COVID-19
K1 Immunosupression
K1 Tocilizumab
K1 Mortality
K1 Risk factor
K1 Platelet
K1 Mortalidad
K1 Factores de riesgo
K1 Plaquetas
AB Tocilizumab (TCZ) has been administered in SARS-CoV-2 pneumonia but the factors associated with mortality before and after treatment remain unclear. Cox regression models were used to estimate the predictors of time to death in a cohort of hospitalized patients with COVID-19 receiving TCZ. In addition, the mean differences between discharged and deceased patients in laboratory parameters measured before and 3, 6 and 9 days after TCZ administration were estimated with weighted generalized estimation equations. The variables associated with time to death were immunosuppression (Hazard Ratio-HR 3.15; 95% confidence interval-CI 1.17, 8.51), diabetes mellitus (HR 2.63; 95% CI 1.23-5.64), age (HR 1.05; 95% CI 1.02-1.09), days since diagnosis until TCZ administration (HR 1.05, 95% CI 1.00-1.09), and platelets (HR 0.27; 95% CI: 0.11, 0.69). In the post-TCZ analysis and compared to discharged patients, deceased patients had more lactate dehydrogenase (p = 0.013), troponin I (p = 0.013), C-reactive protein (p = 0.013), neutrophils (p = 0.024), and fewer platelets (p = 0.013) and lymphocytes (p = 0.013) as well as a lower average PaO2/FiO2 ratio. In conclusion, in COVID-19 diagnosed patients receiving TCZ, early treatment decreased the risk of death, while age, some comorbidities and baseline lower platelet counts increased that risk. After TCZ administration, lower platelet levels were again associated with mortality, together with other laboratory parameters.
PB Frontiers Research Foundation
YR 2021
FD 2021-07-01
LK http://hdl.handle.net/10668/3484
UL http://hdl.handle.net/10668/3484
LA en
NO Sarabia-De Ardanaz L, Andreu-Ubero JM, Navidad-Fuentes M, Ferrer-González MA, Ruíz-Del Valle V, et al. Tocilizumab in COVID-19: Factors Associated With Mortality Before and After Treatment. Front Pharmacol. 2021;12:620187.
DS RISalud
RD Apr 8, 2025